The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Focusing on quality of life for patients with non-small cell lung cancer
Andrea Filippi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, comments on how clinicians can further individualize treatment decisions to optimize outcomes in unresectable non-small cell lung cancer (NSCLC). Whilst personalized therapies are defined by biomarkers and other biological factors, treatments should also be tailed towards the personal circumstances of patients in terms of financial and social needs. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
